Business, energy, technology, markets and global industry news from Business News Today

IMPROVE-PAH

PharmaDeviceNews IMPROVE-PAH
Representative image: Clinical researchers review cardiopulmonary data and oral therapy options as Inhibikase Therapeutics advances IKT-001 in a pivotal Phase 3 trial for pulmonary arterial hypertension following FDA Orphan Drug Designation.
Pharma & Biotech

Inhibikase Therapeutics gains FDA orphan status for IKT-001 as pivotal PAH trial advances

Inhibikase Therapeutics wins FDA orphan status for IKT-001 as its pivotal PAH trial tests whether a prodrug can improve imatinib tolerability.

Read More
Pharma & Biotech

Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst

Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.

Read More